Analysts Predict Shipments of Illumina's MiSeq will Top 600 in 2012 as HiSeq Orders Continue to Grow | GenomeWeb

By Monica Heger

Investment firm William Blair & Company projects that Illumina's sequencing business will continue to demonstrate rapid growth over the next several years, with revenues for the HiSeq set to increase in the range of 20 percent to 25 percent per quarter and orders for the upcoming MiSeq platform "building nicely."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.